Revenue · FY 2026
₹27,958 Cr
▲ 23.12% YoY
EBITDA · FY 2026
₹9,240.45 Cr
▲ 68.65% YoY
Net profit · FY 2026
₹5,355.47 Cr
▲ 61.98% YoY
Authorised capital
₹200 Cr
Registered with MCA
Paid-up capital
₹91.35 Cr
Issued & subscribed
Open charges
₹350 Cr
Satisfied ₹3,238.99 Cr
Company age
43 yrs
Est. 1983
Employees · EPFO
19,688
Latest available
About Lupin Limited
Data last updated: 05 January 2026
Lupin Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 01 March 1983, the company has been in operation for over 43 years.
Registered with ROC Mumbai under CIN L24100MH1983PLC029442. Listed on BSE: 500257 and NSE: LUPIN.
Capital: an authorised share capital of ₹200 Cr and a paid-up capital of ₹91.35 Cr. Formerly known as Lupin Laboratories Limited and Lajwanti Consultants and Builders Private Limited. It is led by directors including Kanwar Bir Singh Anand and Swaminathan Ramesh.
Last AGM: 11 August 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹22,904 Cr, a growth of 14% compared to the previous year.
The company has a workforce of approximately 19,688 employees as per the latest available data. Its group structure includes 5 subsidiaries.
The company is associated with 3 brands - Humrahi, Lupin Diagnostics, Lupin. As per MCA filings, the company has open charges of ₹350 Cr and satisfied charges of ₹3,238.99 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lupin.com.
Company Details of Lupin Limited
CIN
L24100MH1983PLC029442
Registration Number
029442
Incorporation Date
01 March 1983
ROC
Mumbai
Listing Status
Listed (BSE: 500257, NSE: LUPIN)
Company Status
Active
Date of Last AGM
11 August 2025
Date of Balance Sheet
31 March 2025
Compliance Status
Active Compliant
Key People
Nilesh Deshbandhu Gupta Managing Director
Swaminathan Ramesh Whole-Time Director
Vinita Deshbandhu Gupta Whole-Time Director
Contact Details
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressKalpataru Inspire 3Rd Floor Off Western Express Highway Santacruz (, East), Mumbai, Maharashtra, India – 400055
-
IndustryPharma, Drug Formulation & Development, API Manufacturers
Company report
Lupin Limited - full intelligence report
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
₹799
₹999
20% off
Secure checkout · GST invoice included
Name History of Lupin Limited
Lupin Limited has undergone 4 name changes throughout its history. The current legal name is Lupin Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Lupin Limited | Current |
| Lupin Laboratories Limited | Previous |
| Lajwanti Consultants And Builders Private Limited | Previous |
| Lupin Chemicals Limited | Previous |
| Lupin Laboratories Private Limited | Previous |
CIN History of Lupin Limited
Lupin Limited has one previous CIN (Corporate Identification Number): U24100MH1983PLC029442. The current CIN is L24100MH1983PLC029442, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24100MH1983PLC029442 | Current |
| U24100MH1983PLC029442 | Previous |
Associated Brands with Lupin Limited
Lupin Limited operates multiple associated brands including Humrahi, Lupin Diagnostics, and Lupin. These brands represent Lupin Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Delivers an app-based program for effective diabetes management and patient support. | humrahi.co.in | |
| Operates a chain of pathology laboratory centers for diagnostic services. | lupindiagnostics.com | |
| Pharmaceutical products including generics, biosimilars, and APIs are manufactured. | lupin.com |
Competitors & Alternatives of Lupin Limited
Brands and companies operating in the same space as Lupin Limited include Dr Lal PathLabs, Redcliffe Labs, Metropolis India and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Dr Lal PathLabs
|
Chain of pathology and radiology labs | Gurugram, India, India | 1949 |
Redcliffe Labs
|
Home-based diagnostic tests are booked via an online platform. | Noida, India, India | 2018 |
Metropolis India
|
Diagnostic centers are operated as a nationwide chain. | Mumbai, India, India | 1981 |
Orange health
|
At-home diagnostic tests are booked and collected by phlebotomists. | Bengaluru, India, India | 2020 |
Agilus Diagnostics
|
Leading diagnostic chain providing quality blood test and full body checkup services | Gurugram, India, India | 1995 |
Apollo Diagnostics
|
Provides pathology lab tests, health check packages, and home sample collection. | Hyderabad, India, India | 2015 |
Sterling Accuris Diagnostics
|
Pathology diagnostic services are offered via a chain of labs. | Ahmedabad, India, India | 2015 |
Airmed
|
Provider of a chain of diagnostic labs | Ahmedabad, India, India | 2016 |
Oxyjon
|
Health records are stored online for emergency support and sharing. | Gurugram, India, India | 2016 |
Freedom from Diabetes
|
Offers an online platform with personalized programs for effective diabetes management. | Pune, India, India | 2013 |
Business Activity of Lupin Limited
Lupin Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Lupin Limited
Lupin Limited is audited by BSR & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| BSR & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Lupin Limited
Lupin Limited is currently managed by 13 directors, with 28 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kanwar Bir Singh Anand | Director | 12 Aug 2020 | 5 Years 10 Months | Current |
|
Swaminathan Ramesh
Also directs:
Lupin Manufacturing Solutions Limited, Lupin Diagnostics Limited, Lupinlife Consumer Healthcare Limited and 4 more
|
Whole-Time Director | 26 Mar 2020 | 6 Years 3 Months | Current |
| Mark Daniel Mc Dade | Director | 28 Jan 2021 | 5 Years 5 Months | Current |
|
Nilesh Deshbandhu Gupta
Also directs:
Lupin Manufacturing Solutions Limited, Lupin Diagnostics Limited, Polynova Industries Limited and 5 more
|
Managing Director | 01 Sep 2013 | 12 Years 10 Months | Current |
| Punita Lal | Director | 14 May 2025 | 1 Years 1 Months | Current |
| Alfonso Martin Gimenez Zulueta | Director | 06 May 2024 | 2 Years 2 Months | Current |
Showing 6 of 13 current directors. View all directors
Financials of Lupin Limited FY 2026 filings available
Lupin Limited reported revenue of ₹27,958 Cr (up 23.12% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
Revenue · FY 2026
₹27,958 Cr
▲ 23.12%
Profit · FY 2026
₹5,355.47 Cr
▲ 61.98%
EBITDA · FY 2026
₹9,240.45 Cr
▲ 68.65%
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹27,958 Cr | ₹22,708 Cr | ₹20,011 Cr | ₹16,642 Cr | ₹16,405 Cr | ₹15,163 Cr | ₹15,375 Cr |
| Other Income | ₹424.45 Cr | ₹195.82 Cr | ₹120.17 Cr | ₹73.36 Cr | ₹141.69 Cr | ₹136.29 Cr | ₹483.76 Cr |
| Total Income | ₹28,382 Cr | ₹22,904 Cr | ₹20,131 Cr | ₹16,715 Cr | ₹16,547 Cr | ₹15,299 Cr | ₹15,859 Cr |
| Cost of Materials Consumed | ₹4,621.9 Cr | ₹4,457.41 Cr | ₹4,142.19 Cr | ₹3,687.81 Cr | ₹3,235.71 Cr | ₹3,169.79 Cr | ₹3,163.82 Cr |
| Purchases of Stock-in-Trade | ₹2,867.01 Cr | ₹2,642.62 Cr | ₹2,958.72 Cr | ₹2,938.22 Cr | ₹3,443.85 Cr | ₹2,677.31 Cr | ₹2,258.23 Cr |
| Changes in Inventories | -₹162.45 Cr | -₹257.78 Cr | -₹457.44 Cr | ₹153.73 Cr | -₹198.32 Cr | -₹484.86 Cr | ₹8.55 Cr |
| Employee Benefit Expense | ₹4,574.53 Cr | ₹3,964.2 Cr | ₹3,494.57 Cr | ₹3,087.15 Cr | ₹2,989.3 Cr | ₹2,825.9 Cr | ₹2,986.84 Cr |
| Finance Costs | ₹434.49 Cr | ₹294.87 Cr | ₹311.61 Cr | ₹274.3 Cr | ₹142.77 Cr | ₹140.64 Cr | ₹362.98 Cr |
| Depreciation & Amortisation | ₹1,375.5 Cr | ₹1,169.26 Cr | ₹1,196.81 Cr | ₹880.69 Cr | ₹1,658.71 Cr | ₹887.41 Cr | ₹970.22 Cr |
| Other Expenses | ₹7,241.04 Cr | ₹6,618.14 Cr | ₹6,062.26 Cr | ₹4,976.63 Cr | ₹6,647.72 Cr | ₹4,407.94 Cr | ₹4,602.52 Cr |
| Total Expenses | ₹20,952 Cr | ₹18,889 Cr | ₹17,709 Cr | ₹15,999 Cr | ₹17,920 Cr | ₹13,624 Cr | ₹14,353 Cr |
| Profit Before Exceptional Items & Tax | ₹7,430.46 Cr | ₹4,015 Cr | ₹2,422.27 Cr | ₹716.49 Cr | -₹1,372.57 Cr | ₹1,675.12 Cr | ₹1,505.36 Cr |
| Exceptional Items | -₹557.91 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹752.07 Cr |
| Profit Before Tax | ₹6,872.55 Cr | ₹4,015 Cr | ₹2,422.27 Cr | ₹716.49 Cr | -₹1,372.57 Cr | ₹1,675.12 Cr | ₹753.29 Cr |
| Total Tax Expense | ₹1,517.08 Cr | ₹708.74 Cr | ₹486.7 Cr | ₹268.8 Cr | ₹137.15 Cr | ₹448.52 Cr | ₹1,157.11 Cr |
| Net Profit | ₹5,355.47 Cr | ₹3,306.26 Cr | ₹1,935.57 Cr | ₹447.69 Cr | -₹1,509.36 Cr | ₹1,227.93 Cr | -₹269.78 Cr |
| attributable to Owners | ₹5,332.84 Cr | ₹3,281.62 Cr | ₹1,914.48 Cr | ₹430.08 Cr | -₹1,528.04 Cr | ₹1,216.53 Cr | -₹610.53 Cr |
| attributable to NCI | ₹22.63 Cr | ₹24.64 Cr | ₹21.09 Cr | ₹17.61 Cr | ₹18.68 Cr | ₹11.4 Cr | ₹2.7 Cr |
| Other Comprehensive Income | ₹440.4 Cr | -₹91.47 Cr | ₹37.6 Cr | ₹24.22 Cr | ₹104.01 Cr | ₹262.01 Cr | -₹607.78 Cr |
| Total Comprehensive Income | ₹5,795.87 Cr | ₹3,214.79 Cr | ₹1,973.17 Cr | ₹471.91 Cr | -₹1,405.35 Cr | ₹1,489.94 Cr | -₹877.56 Cr |
| EBITDA (computed) | ₹9,240.45 Cr | ₹5,479.13 Cr | ₹3,930.69 Cr | ₹1,871.48 Cr | ₹428.91 Cr | ₹2,703.17 Cr | ₹2,838.56 Cr |
| Basic EPS | ₹116.75 | ₹71.95 | ₹42.05 | ₹9.46 | ₹-33.65 | ₹27.09 | ₹-8.83 |
| Diluted EPS | ₹116.44 | ₹71.69 | ₹41.87 | ₹9.41 | ₹-33.65 | ₹26.97 | ₹-8.83 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹38,365 Cr | ₹29,205 Cr | ₹23,997 Cr | ₹22,956 Cr |
| Non-current Assets | ₹14,337 Cr | ₹12,406 Cr | ₹10,550 Cr | ₹10,505 Cr |
| Current Assets | ₹24,027 Cr | ₹16,799 Cr | ₹13,448 Cr | ₹12,451 Cr |
| Property, Plant & Equipment | ₹5,449.1 Cr | ₹5,148.18 Cr | ₹4,898.55 Cr | ₹4,645.02 Cr |
| Inventories | ₹6,083.25 Cr | ₹5,476.35 Cr | ₹4,953.9 Cr | ₹4,491.76 Cr |
| Trade Receivables | ₹6,604.06 Cr | ₹5,497.1 Cr | ₹4,692.05 Cr | ₹4,480.7 Cr |
| Cash & Equivalents | ₹4,167.73 Cr | ₹1,543.69 Cr | ₹983.28 Cr | ₹1,231.81 Cr |
| Equity (Net Worth) | ₹22,513 Cr | ₹17,294 Cr | ₹14,373 Cr | ₹12,543 Cr |
| Equity Share Capital | ₹91.44 Cr | ₹91.32 Cr | ₹91.14 Cr | ₹91 Cr |
| Borrowings (Non-current) | ₹1,643.39 Cr | ₹1,766.23 Cr | ₹0 | ₹27.51 Cr |
| Borrowings (Current) | ₹4,266.81 Cr | ₹3,310.42 Cr | ₹2,669.91 Cr | ₹4,216.54 Cr |
| Total Debt (computed) | ₹5,910.2 Cr | ₹5,076.65 Cr | ₹2,669.91 Cr | ₹4,244.05 Cr |
| Current Liabilities | ₹12,651 Cr | ₹8,961.39 Cr | ₹8,501.5 Cr | ₹9,265.37 Cr |
| Total Liabilities | ₹15,851 Cr | ₹11,911 Cr | ₹9,623.73 Cr | ₹10,413 Cr |
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹7,545.63 Cr | ₹429.94 Cr | ₹3,490.43 Cr | ₹1,934.12 Cr | ₹1,082.38 Cr |
| Investing Cash Flow | -₹4,075.72 Cr | -₹1,601.89 Cr | -₹1,554.27 Cr | -₹1,323.91 Cr | ₹577.16 Cr |
| Financing Cash Flow | -₹845.87 Cr | ₹1,731.88 Cr | -₹2,184.21 Cr | -₹336.99 Cr | -₹1,572.32 Cr |
| Capital Expenditure | ₹2,054.85 Cr | ₹1,682.43 Cr | ₹928.9 Cr | ₹1,499.62 Cr | ₹905.08 Cr |
| Free Cash Flow (computed) | ₹5,490.78 Cr | -₹1,252.49 Cr | ₹2,561.53 Cr | ₹434.5 Cr | ₹177.3 Cr |
| Dividends Paid | ₹548.34 Cr | ₹365.31 Cr | ₹182.8 Cr | ₹182.5 Cr | ₹295.09 Cr |
| Net Change in Cash | ₹2,624.04 Cr | ₹559.93 Cr | -₹248.05 Cr | ₹273.22 Cr | ₹65.15 Cr |
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7,474.66 Cr | ₹7,167.52 Cr | ₹7,047.51 Cr | ₹6,268.34 Cr | ₹5,667.13 Cr | ₹5,767.71 Cr | ₹5,672.73 Cr | ₹5,600.33 Cr | ₹4,960.79 Cr | ₹5,197.41 Cr | ₹5,038.56 Cr | ₹4,814.06 Cr |
| Other Income | ₹140.71 Cr | ₹114.7 Cr | ₹90 Cr | ₹79.04 Cr | ₹56.95 Cr | ₹53.71 Cr | ₹42.29 Cr | ₹67.78 Cr | ₹29.25 Cr | ₹29.37 Cr | ₹40.4 Cr | ₹22.83 Cr |
| Total Income | ₹7,615.37 Cr | ₹7,282.22 Cr | ₹7,137.51 Cr | ₹6,347.38 Cr | ₹5,724.08 Cr | ₹5,821.42 Cr | ₹5,715.02 Cr | ₹5,668.11 Cr | ₹4,990.04 Cr | ₹5,226.78 Cr | ₹5,078.96 Cr | ₹4,836.89 Cr |
| Cost of Materials Consumed | ₹1,231.3 Cr | ₹1,124.82 Cr | ₹1,139.15 Cr | ₹1,126.63 Cr | ₹1,109.46 Cr | ₹1,084.09 Cr | ₹1,118.12 Cr | ₹1,145.74 Cr | ₹1,094.41 Cr | ₹1,106.73 Cr | ₹990.99 Cr | ₹950.06 Cr |
| Purchases of Stock-in-Trade | ₹708.41 Cr | ₹719.73 Cr | ₹724.92 Cr | ₹713.95 Cr | ₹575.69 Cr | ₹766.39 Cr | ₹659.98 Cr | ₹640.56 Cr | ₹661.11 Cr | ₹676.12 Cr | ₹854.74 Cr | ₹766.75 Cr |
| Changes in Inventories | -₹88.08 Cr | ₹33.58 Cr | -₹39.3 Cr | -₹68.65 Cr | ₹1.05 Cr | -₹128.93 Cr | -₹88.16 Cr | -₹41.74 Cr | -₹181.68 Cr | -₹56.77 Cr | -₹142.96 Cr | -₹76.03 Cr |
| Employee Benefit Expense | ₹1,242.69 Cr | ₹1,143.28 Cr | ₹1,105.56 Cr | ₹1,083 Cr | ₹1,001.25 Cr | ₹984.39 Cr | ₹1,007.52 Cr | ₹971.04 Cr | ₹900.22 Cr | ₹889.24 Cr | ₹860.71 Cr | ₹844.4 Cr |
| Finance Costs | ₹120.16 Cr | ₹114.98 Cr | ₹107.59 Cr | ₹91.76 Cr | ₹89.1 Cr | ₹66.89 Cr | ₹70.87 Cr | ₹68.01 Cr | ₹71.29 Cr | ₹74.01 Cr | ₹80.64 Cr | ₹85.67 Cr |
| Depreciation & Amortisation | ₹446.79 Cr | ₹312.96 Cr | ₹316.77 Cr | ₹298.98 Cr | ₹393.18 Cr | ₹271.45 Cr | ₹256.92 Cr | ₹247.71 Cr | ₹457.1 Cr | ₹257.2 Cr | ₹247.85 Cr | ₹234.66 Cr |
| Other Expenses | ₹1,894.76 Cr | ₹1,884.26 Cr | ₹1,775.85 Cr | ₹1,686.17 Cr | ₹1,658.51 Cr | ₹1,705.87 Cr | ₹1,634.91 Cr | ₹1,643.76 Cr | ₹1,489.88 Cr | ₹1,544.15 Cr | ₹1,557.32 Cr | ₹1,472.59 Cr |
| Total Expenses | ₹5,556.03 Cr | ₹5,333.61 Cr | ₹5,130.54 Cr | ₹4,931.84 Cr | ₹4,828.24 Cr | ₹4,750.15 Cr | ₹4,660.16 Cr | ₹4,675.08 Cr | ₹4,492.33 Cr | ₹4,490.68 Cr | ₹4,449.29 Cr | ₹4,278.1 Cr |
| Profit Before Exceptional Items & Tax | ₹2,059.34 Cr | ₹1,948.61 Cr | ₹2,006.97 Cr | ₹1,415.54 Cr | ₹895.84 Cr | ₹1,071.27 Cr | ₹1,054.86 Cr | ₹993.03 Cr | ₹497.71 Cr | ₹736.1 Cr | ₹629.67 Cr | ₹558.79 Cr |
| Exceptional Items | -₹131.34 Cr | -₹426.57 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1,928 Cr | ₹1,522.04 Cr | ₹2,006.97 Cr | ₹1,415.54 Cr | ₹895.84 Cr | ₹1,071.27 Cr | ₹1,054.86 Cr | ₹993.03 Cr | ₹497.71 Cr | ₹736.1 Cr | ₹629.67 Cr | ₹558.79 Cr |
| Total Tax Expense | ₹459.33 Cr | ₹341.53 Cr | ₹522.14 Cr | ₹194.08 Cr | ₹113.46 Cr | ₹212.41 Cr | ₹195.38 Cr | ₹187.49 Cr | ₹129.49 Cr | ₹117.4 Cr | ₹134.35 Cr | ₹105.46 Cr |
| Net Profit | ₹1,468.67 Cr | ₹1,180.51 Cr | ₹1,484.83 Cr | ₹1,221.46 Cr | ₹782.38 Cr | ₹858.86 Cr | ₹859.48 Cr | ₹805.54 Cr | ₹368.22 Cr | ₹618.7 Cr | ₹495.32 Cr | ₹453.33 Cr |
| attributable to Owners | ₹1,460.34 Cr | ₹1,175.55 Cr | ₹1,477.92 Cr | ₹1,219.03 Cr | ₹772.52 Cr | ₹855.16 Cr | ₹852.63 Cr | ₹801.31 Cr | ₹359.43 Cr | ₹613.12 Cr | ₹489.67 Cr | ₹452.26 Cr |
| attributable to NCI | ₹8.33 Cr | ₹4.96 Cr | ₹6.91 Cr | ₹2.43 Cr | ₹9.86 Cr | ₹3.7 Cr | ₹6.85 Cr | ₹4.23 Cr | ₹8.79 Cr | ₹5.58 Cr | ₹5.65 Cr | ₹1.07 Cr |
| Other Comprehensive Income | ₹64.26 Cr | ₹120.1 Cr | ₹95.82 Cr | ₹160.22 Cr | ₹23.03 Cr | -₹119.53 Cr | ₹57.69 Cr | -₹52.66 Cr | -₹27.14 Cr | ₹78.18 Cr | ₹22.38 Cr | -₹35.82 Cr |
| Total Comprehensive Income | ₹1,532.93 Cr | ₹1,300.61 Cr | ₹1,580.65 Cr | ₹1,381.68 Cr | ₹805.41 Cr | ₹739.33 Cr | ₹917.17 Cr | ₹752.88 Cr | ₹341.08 Cr | ₹696.88 Cr | ₹517.7 Cr | ₹417.51 Cr |
| EBITDA (computed) | ₹2,626.29 Cr | ₹2,376.55 Cr | ₹2,431.33 Cr | ₹1,806.28 Cr | ₹1,378.12 Cr | ₹1,409.61 Cr | ₹1,382.65 Cr | ₹1,308.75 Cr | ₹1,026.1 Cr | ₹1,067.31 Cr | ₹958.16 Cr | ₹879.12 Cr |
| Basic EPS | ₹31.96 | ₹25.74 | ₹32.36 | ₹26.70 | ₹16.93 | ₹18.75 | ₹18.70 | ₹17.58 | ₹7.89 | ₹13.47 | ₹10.76 | ₹9.94 |
| Diluted EPS | ₹31.89 | ₹25.67 | ₹32.28 | ₹26.62 | ₹16.87 | ₹18.69 | ₹18.64 | ₹17.52 | ₹7.86 | ₹13.41 | ₹10.72 | ₹9.90 |
Latest 12 quarters shown of 24 on record.
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹7,434.74 Cr | ₹1,977.1 Cr | ₹38,129 Cr | ₹15,746 Cr |
| Others | ₹40.47 Cr | -₹49.1 Cr | ₹239.46 Cr | ₹108.47 Cr |
| Less: Inter segment Assets | ₹0 | ₹0 | -₹3.23 Cr | ₹0 |
| Less: Inter segment Liabilities | ₹0 | ₹0 | ₹0 | -₹3.23 Cr |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹27,812 Cr | ₹7,050.27 Cr | - | - |
| Others | ₹147.39 Cr | -₹177.72 Cr | - | - |
| Less: Inter segment Assets | ₹0 | ₹0 | - | - |
| Less: Inter segment Liabilities | ₹0 | ₹0 | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹19,513 Cr | ₹16,968 Cr | ₹14,667 Cr | ₹11,259 Cr | ₹11,772 Cr | ₹11,056 Cr | ₹11,026 Cr |
| Other Income | ₹312.77 Cr | ₹174.05 Cr | ₹106.73 Cr | ₹91.26 Cr | ₹150.42 Cr | ₹129.09 Cr | ₹475.19 Cr |
| Total Income | ₹19,825 Cr | ₹17,142 Cr | ₹14,773 Cr | ₹11,350 Cr | ₹11,922 Cr | ₹11,185 Cr | ₹11,501 Cr |
| Cost of Materials Consumed | ₹3,678.36 Cr | ₹3,716.72 Cr | ₹3,407.3 Cr | ₹3,151.2 Cr | ₹2,816.9 Cr | ₹2,741.22 Cr | ₹2,753.22 Cr |
| Purchases of Stock-in-Trade | ₹1,192.32 Cr | ₹1,246.85 Cr | ₹1,633.86 Cr | ₹1,525.7 Cr | ₹1,892.74 Cr | ₹1,522.95 Cr | ₹1,482.77 Cr |
| Changes in Inventories | ₹4.66 Cr | -₹38.35 Cr | -₹15.93 Cr | ₹120.79 Cr | -₹242.38 Cr | -₹81.86 Cr | -₹28.72 Cr |
| Employee Benefit Expense | ₹2,544.88 Cr | ₹2,312.07 Cr | ₹2,095.51 Cr | ₹1,934.14 Cr | ₹1,918.16 Cr | ₹1,695.86 Cr | ₹1,703.22 Cr |
| Finance Costs | ₹121.47 Cr | ₹84.5 Cr | ₹56.35 Cr | ₹98.44 Cr | ₹73.47 Cr | ₹40.62 Cr | ₹52.59 Cr |
| Depreciation & Amortisation | ₹707.18 Cr | ₹647.69 Cr | ₹724.75 Cr | ₹548.34 Cr | ₹514.19 Cr | ₹502.83 Cr | ₹518.75 Cr |
| Other Expenses | ₹4,288.88 Cr | ₹4,257.73 Cr | ₹4,086.7 Cr | ₹3,444.34 Cr | ₹5,110.54 Cr | ₹3,133.7 Cr | ₹3,207.56 Cr |
| Total Expenses | ₹12,538 Cr | ₹12,227 Cr | ₹11,989 Cr | ₹10,823 Cr | ₹12,084 Cr | ₹9,555.32 Cr | ₹9,689.39 Cr |
| Profit Before Exceptional Items & Tax | ₹7,287.68 Cr | ₹4,914.34 Cr | ₹2,784.69 Cr | ₹527.14 Cr | -₹161.53 Cr | ₹1,629.7 Cr | ₹1,811.46 Cr |
| Exceptional Items | ₹406.57 Cr | -₹77.22 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹759.21 Cr |
| Profit Before Tax | ₹7,694.25 Cr | ₹4,837.12 Cr | ₹2,784.69 Cr | ₹527.14 Cr | -₹161.53 Cr | ₹1,629.7 Cr | ₹1,052.25 Cr |
| Total Tax Expense | ₹1,327.69 Cr | ₹864.16 Cr | ₹458.6 Cr | ₹101.93 Cr | ₹27.17 Cr | ₹371.08 Cr | ₹324.7 Cr |
| Net Profit | ₹6,366.56 Cr | ₹3,972.96 Cr | ₹2,326.09 Cr | ₹425.21 Cr | -₹188.7 Cr | ₹1,258.62 Cr | ₹727.55 Cr |
| Other Comprehensive Income | -₹17.08 Cr | -₹14.47 Cr | -₹4.69 Cr | -₹23.92 Cr | ₹1.03 Cr | ₹44.69 Cr | -₹69.25 Cr |
| Total Comprehensive Income | ₹6,349.48 Cr | ₹3,958.49 Cr | ₹2,321.4 Cr | ₹401.29 Cr | -₹187.67 Cr | ₹1,303.31 Cr | ₹658.3 Cr |
| EBITDA (computed) | ₹8,116.33 Cr | ₹5,646.53 Cr | ₹3,565.79 Cr | ₹1,173.92 Cr | ₹426.13 Cr | ₹2,173.15 Cr | ₹2,382.8 Cr |
| Basic EPS | ₹139.38 | ₹87.10 | ₹51.10 | ₹9.35 | ₹-4.16 | ₹27.77 | ₹16.07 |
| Diluted EPS | ₹139.01 | ₹86.79 | ₹50.87 | ₹9.31 | ₹-4.16 | ₹27.65 | ₹15.99 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹36,103 Cr | ₹28,432 Cr | ₹24,923 Cr | ₹22,684 Cr |
| Non-current Assets | ₹20,508 Cr | ₹16,537 Cr | ₹15,635 Cr | ₹15,113 Cr |
| Current Assets | ₹15,595 Cr | ₹11,895 Cr | ₹9,140.18 Cr | ₹7,570.92 Cr |
| Property, Plant & Equipment | ₹3,168.51 Cr | ₹3,445.67 Cr | ₹3,498.22 Cr | ₹3,677.82 Cr |
| Inventories | ₹3,350.78 Cr | ₹3,227.22 Cr | ₹2,969.31 Cr | ₹3,019.47 Cr |
| Trade Receivables | ₹6,922.03 Cr | ₹5,664.35 Cr | ₹3,842.15 Cr | ₹2,674.42 Cr |
| Cash & Equivalents | ₹111.63 Cr | ₹341.8 Cr | ₹123.7 Cr | ₹85.66 Cr |
| Equity (Net Worth) | ₹30,134 Cr | ₹24,278 Cr | ₹20,603 Cr | ₹18,412 Cr |
| Equity Share Capital | ₹91.44 Cr | ₹91.32 Cr | ₹91.14 Cr | ₹91 Cr |
| Borrowings (Non-current) | ₹0 | ₹225.84 Cr | ₹0 | ₹0 |
| Borrowings (Current) | ₹576.88 Cr | ₹0 | ₹18.13 Cr | ₹613.46 Cr |
| Total Debt (computed) | ₹576.88 Cr | ₹225.84 Cr | ₹18.13 Cr | ₹613.46 Cr |
| Current Liabilities | ₹4,832.33 Cr | ₹3,232.52 Cr | ₹3,646.42 Cr | ₹3,627.85 Cr |
| Total Liabilities | ₹5,969.12 Cr | ₹4,153.75 Cr | ₹4,319.77 Cr | ₹4,271.81 Cr |
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹5,539.85 Cr | ₹2,444.65 Cr | ₹2,504.91 Cr | ₹1,784.55 Cr | ₹252.17 Cr |
| Investing Cash Flow | -₹5,648.89 Cr | -₹1,766.32 Cr | -₹1,599.8 Cr | -₹1,259.73 Cr | -₹472.93 Cr |
| Financing Cash Flow | -₹121.13 Cr | -₹460.23 Cr | -₹867.07 Cr | -₹498.26 Cr | ₹102.45 Cr |
| Capital Expenditure | ₹717.04 Cr | ₹1,294.38 Cr | ₹698.54 Cr | ₹575.13 Cr | ₹597.2 Cr |
| Free Cash Flow (computed) | ₹4,822.81 Cr | ₹1,150.27 Cr | ₹1,806.37 Cr | ₹1,209.42 Cr | -₹345.03 Cr |
| Dividends Paid | ₹548.34 Cr | ₹365.31 Cr | ₹182.8 Cr | ₹182.5 Cr | ₹295.09 Cr |
| Net Change in Cash | -₹230.17 Cr | ₹218.1 Cr | ₹38.04 Cr | ₹26.56 Cr | -₹118.31 Cr |
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹5,234.6 Cr | ₹4,501.19 Cr | ₹4,068.28 Cr | ₹5,708.59 Cr | ₹4,485.67 Cr | ₹4,208 Cr | ₹4,106.2 Cr | ₹4,167.63 Cr | ₹3,395.88 Cr | ₹4,115.75 Cr | ₹3,659.23 Cr | ₹3,495.64 Cr |
| Other Income | ₹88.83 Cr | ₹99.8 Cr | ₹70 Cr | ₹54.14 Cr | ₹48.79 Cr | ₹55.3 Cr | ₹32.62 Cr | ₹38.22 Cr | ₹31.34 Cr | ₹23.16 Cr | ₹25.6 Cr | ₹27.74 Cr |
| Total Income | ₹5,323.43 Cr | ₹4,600.99 Cr | ₹4,138.28 Cr | ₹5,762.73 Cr | ₹4,534.46 Cr | ₹4,263.3 Cr | ₹4,138.82 Cr | ₹4,205.85 Cr | ₹3,427.22 Cr | ₹4,138.91 Cr | ₹3,684.83 Cr | ₹3,523.38 Cr |
| Cost of Materials Consumed | ₹995.53 Cr | ₹909.55 Cr | ₹864.14 Cr | ₹909.14 Cr | ₹923.6 Cr | ₹912.78 Cr | ₹907.04 Cr | ₹973.3 Cr | ₹884.81 Cr | ₹836.97 Cr | ₹855.88 Cr | ₹829.64 Cr |
| Purchases of Stock-in-Trade | ₹274.58 Cr | ₹296.13 Cr | ₹309.68 Cr | ₹311.93 Cr | ₹277.74 Cr | ₹331.27 Cr | ₹312.43 Cr | ₹325.41 Cr | ₹344.56 Cr | ₹364.47 Cr | ₹469.29 Cr | ₹455.54 Cr |
| Changes in Inventories | -₹33.51 Cr | -₹17.52 Cr | ₹95.44 Cr | -₹39.75 Cr | -₹25.65 Cr | -₹87.97 Cr | ₹109.75 Cr | -₹34.48 Cr | -₹10.81 Cr | ₹132.47 Cr | -₹98.76 Cr | -₹38.83 Cr |
| Employee Benefit Expense | ₹660.65 Cr | ₹631.51 Cr | ₹608.83 Cr | ₹643.89 Cr | ₹552.42 Cr | ₹576.37 Cr | ₹594.51 Cr | ₹588.77 Cr | ₹517.07 Cr | ₹522.47 Cr | ₹532.18 Cr | ₹523.79 Cr |
| Finance Costs | ₹38.77 Cr | ₹36.02 Cr | ₹27.78 Cr | ₹18.9 Cr | ₹33.85 Cr | ₹19.55 Cr | ₹17.55 Cr | ₹13.55 Cr | ₹13.49 Cr | ₹11.36 Cr | ₹15.32 Cr | ₹16.18 Cr |
| Depreciation & Amortisation | ₹177.05 Cr | ₹178.68 Cr | ₹174.72 Cr | ₹176.73 Cr | ₹207.98 Cr | ₹152.52 Cr | ₹145.77 Cr | ₹141.42 Cr | ₹290.04 Cr | ₹145.18 Cr | ₹149.48 Cr | ₹140.05 Cr |
| Other Expenses | ₹1,055.74 Cr | ₹1,064.84 Cr | ₹1,014.56 Cr | ₹1,153.74 Cr | ₹1,011.43 Cr | ₹1,064.5 Cr | ₹1,067.72 Cr | ₹1,114.96 Cr | ₹959.9 Cr | ₹1,042.03 Cr | ₹1,065.4 Cr | ₹1,020.48 Cr |
| Total Expenses | ₹3,168.81 Cr | ₹3,099.21 Cr | ₹3,095.15 Cr | ₹3,174.58 Cr | ₹2,981.37 Cr | ₹2,969.02 Cr | ₹3,154.77 Cr | ₹3,122.93 Cr | ₹2,999.06 Cr | ₹3,054.95 Cr | ₹2,988.79 Cr | ₹2,946.85 Cr |
| Profit Before Exceptional Items & Tax | ₹2,154.62 Cr | ₹1,501.78 Cr | ₹1,043.13 Cr | ₹2,588.15 Cr | ₹1,553.09 Cr | ₹1,294.28 Cr | ₹984.05 Cr | ₹1,082.92 Cr | ₹428.16 Cr | ₹1,083.96 Cr | ₹696.04 Cr | ₹576.53 Cr |
| Exceptional Items | ₹447.73 Cr | -₹633.84 Cr | ₹592.68 Cr | ₹0 | ₹0 | -₹77.22 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹2,602.35 Cr | ₹867.94 Cr | ₹1,635.81 Cr | ₹2,588.15 Cr | ₹1,553.09 Cr | ₹1,217.06 Cr | ₹984.05 Cr | ₹1,082.92 Cr | ₹428.16 Cr | ₹1,083.96 Cr | ₹696.04 Cr | ₹576.53 Cr |
| Total Tax Expense | ₹438.66 Cr | ₹150.49 Cr | ₹278.46 Cr | ₹460.08 Cr | ₹261.74 Cr | ₹232.39 Cr | ₹176.29 Cr | ₹193.74 Cr | ₹44.08 Cr | ₹167.52 Cr | ₹147.43 Cr | ₹99.57 Cr |
| Net Profit | ₹2,163.69 Cr | ₹717.45 Cr | ₹1,357.35 Cr | ₹2,128.07 Cr | ₹1,291.35 Cr | ₹984.67 Cr | ₹807.76 Cr | ₹889.18 Cr | ₹384.08 Cr | ₹916.44 Cr | ₹548.61 Cr | ₹476.96 Cr |
| Other Comprehensive Income | ₹6.51 Cr | -₹5.88 Cr | -₹15.72 Cr | -₹1.99 Cr | -₹11.63 Cr | ₹11.19 Cr | -₹7.21 Cr | -₹6.82 Cr | ₹1.34 Cr | -₹3.61 Cr | -₹2.91 Cr | ₹49 Lakh |
| Total Comprehensive Income | ₹2,170.2 Cr | ₹711.57 Cr | ₹1,341.63 Cr | ₹2,126.08 Cr | ₹1,279.72 Cr | ₹995.86 Cr | ₹800.55 Cr | ₹882.36 Cr | ₹385.42 Cr | ₹912.83 Cr | ₹545.7 Cr | ₹477.45 Cr |
| EBITDA (computed) | ₹2,370.44 Cr | ₹1,716.48 Cr | ₹1,245.63 Cr | ₹2,783.78 Cr | ₹1,794.92 Cr | ₹1,466.35 Cr | ₹1,147.37 Cr | ₹1,237.89 Cr | ₹731.69 Cr | ₹1,240.5 Cr | ₹860.84 Cr | ₹732.76 Cr |
| Basic EPS | ₹47.35 | ₹15.71 | ₹29.72 | ₹46.60 | ₹28.30 | ₹21.58 | ₹17.71 | ₹19.51 | ₹8.43 | ₹20.14 | ₹12.06 | ₹10.48 |
| Diluted EPS | ₹47.24 | ₹15.67 | ₹29.65 | ₹46.48 | ₹28.21 | ₹21.52 | ₹17.66 | ₹19.44 | ₹8.40 | ₹20.05 | ₹12.01 | ₹10.44 |
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Lupin Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Shareholding Pattern of Lupin Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 46.86%, foreign institutional investors hold 21.71%, domestic institutional investors hold 25.32%, retail and other public shareholders hold 6.11% of Lupin Limited. The company had 290,411 shareholders on record.
Mar 2026
QUARTER
46.86% Promoters
25.32% DII (Domestic Institutional)
21.71% FII (Foreign Institutional)
6.11% Retail & Others
Promoter holding - history
Now 46.86% · Mar 2026High 47.11% · Sep 2022Low 46.52% · Mar 2016
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 46.86% | 46.89% | 46.90% | 46.90% | 46.92% | 46.95% |
| Public | 53.14% | 53.11% | 53.10% | 53.10% | 53.08% | 53.05% |
Shareholding history - year on year (as at 31 March)
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 46.86% | 46.92% | 47.01% | 47.08% | 46.78% | 46.86% | 46.92% | 46.97% | 47.01% | 46.69% | 46.52% |
| Public | 53.14% | 53.08% | 52.99% | 52.92% | 53.22% | 53.14% | 53.08% | 53.03% | 52.99% | 53.31% | 53.48% |
| Promoter change (YoY, %pts) | -0.06 | -0.09 | -0.07 | +0.30 | -0.08 | -0.06 | -0.05 | -0.04 | +0.32 | +0.17 | - |
Board & Governance of Lupin Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Lupin Limited has 10 directors - 6 independent and 3 executive. The board is chaired by Manju D. Gupta.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Manju D. Gupta | Non-Executive - Non Independent Director · Chairperson | 1983-03-01 | 1 |
| Vinita Gupta | Executive Director · CEO | 2001-08-17 | 1 |
| Nilesh D. Gupta | Executive Director · MD | 2008-10-08 | 1 |
| Ramesh Swaminathan | Executive Director | 2020-03-26 | 1 |
| Kanwar Bir Singh Anand | Non-Executive - Independent Director | 2020-08-12 | 6 |
| Mark D. McDade | Non-Executive - Independent Director | 2021-01-28 | 1 |
| Jeffrey Kindler | Non-Executive - Independent Director | 2024-05-06 | 1 |
| Alfonso Zulueta | Non-Executive - Independent Director | 2024-05-06 | 1 |
| Punita Lal | Non-Executive - Independent Director | 2025-05-14 | 1 |
| Anand Kripalu | Non-Executive - Independent Director | 2026-02-01 | 4 |
Board Committees
| Committee | Members |
|---|---|
| Audit Committee | Kanwar Bir Singh Anand (Chairperson), Alfonso Zulueta, Mark D. McDade, Anand Kripalu |
| Nomination and remuneration committee | Mark D. McDade (Chairperson), Punita Lal, Kanwar Bir Singh Anand |
| Stakeholders Relationship Committee | Kanwar Bir Singh Anand (Chairperson), Nilesh D. Gupta, Ramesh Swaminathan |
| Risk Management Committee | Jeffrey Kindler (Chairperson), Vinita Gupta, Nilesh D. Gupta, Ramesh Swaminathan, Mark D. McDade, Punita Lal |
| Corporate Social Responsibility Committee | Manju D. Gupta (Chairperson), Vinita Gupta, Nilesh D. Gupta, Kanwar Bir Singh Anand, Anand Kripalu |
Group Structure of Lupin Limited
Lupin Limited has 5 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Lupin Limited's business expansion strategy and organizational complexity.
5
Subsidiary companies
Key Subsidiaries
| Company Name | CIN | Shares Held |
|---|---|---|
| Lupin Manufacturing Solutions Ltd., India (W.E.F. July 24, 2023) | U21001MH2023PLC407210 | - |
| Lupin Diagnostics Ltd., India | U24100MH2011PLC214885 | - |
| Lupin Biologics Ltd., India | U24299MH2021PLC354211 | - |
| Lupin Digital Health Ltd., India | U74999MH2021PLC360783 | - |
| Lupin Life Sciences Ltd., India (Formerly Known As Lupin Atharv Ability Ltd.)(W.E.F. July 17, 2023) | U86100MH2023PLC406793 | - |
Showing major subsidiaries. Total: 5.
Charges & Borrowings of Lupin Limited
Open charges
₹350 Cr
Satisfied charges
₹3,238.99 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Feb 2022 | Others | ₹100 Cr | Open |
| 17 Feb 2022 | Others | ₹200 Cr | Open |
| 27 Dec 2021 | State Bank of India | ₹50 Cr | Open |
| 04 Jun 2007 | State Bank of India | ₹52.1 Cr | Satisfied |
| 01 Aug 2006 | State Bank of India | ₹52.1 Cr | Satisfied |
Total charge records: 148 View all charges
Employees and EPFO Compliance at Lupin Limited
Lupin Limited has a workforce of 19,688 employees as of Mar 22, 2025.
Employee count
19,688
Active EPFO establishments
12
Employee growth
0.51%
Employee Count & EPFO Data of Lupin Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification
GST Compliance of Lupin Limited
XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS
GSTIN & GST Filing Data of Lupin Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution
Credit Ratings, Litigation & Regulatory Alerts for Lupin Limited
Credit rating
2015
2017
2019
2021
2023
Litigation
District Court
35
High Court
45
Supreme Court
0
NCLT / NCLAT
0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults
Credit Ratings, Legal Cases & Regulatory Alerts of Lupin Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)
MSME Payment Delays by Lupin Limited
MSME Payment Delays by Lupin Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal
Subsidiaries & Group Companies of Lupin Limited
Subsidiaries & Group Companies of Lupin Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Lupin Limited with ownership details.
Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year
MCA Filings & Documents of Lupin Limited
MCA Filings & Documents of Lupin Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates
Recent Activity on Lupin Limited
Activity
11 Aug 2025
Lupin Limited last Annual general meeting of members was held on 11 Aug 2025 as per latest MCA records.
Directors
14 May 2025
Punita Lal was appointed as a Director on 14 May 2025 & has been associated with this company since 1 year 1 month.
Activity
31 Mar 2025
Lupin Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Directors
05 Sep 2024
Amit Kumar Gupta was appointed as a Nodal Officer on 05 Sep 2024 & has been associated with this company since 1 year 10 months.
Directors
03 Sep 2024
Amit Kumar Gupta was appointed as a Company Secretary on 03 Sep 2024 & has been associated with this company since 1 year 10 months.
Directors
06 May 2024
Alfonso Martin Gimenez Zulueta was appointed as a Director on 06 May 2024 & has been associated with this company since 2 years 2 months.
Recent News on Lupin Limited
Frequently Asked Questions about Lupin Limited
Lupin Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 01 March 1983 (43+ years old) and is registered under CIN L24100MH1983PLC029442. Listed on BSE: 500257 and NSE: LUPIN. The company has 19,688 employees.
Lupin Limited reported revenue of ₹22,904 Cr for FY 2025 (up 14.00% YoY).
The current directors of Lupin Limited are:
- Kanwar Bir Singh Anand
- Swaminathan Ramesh
- Ramesh Swaminathan
- Mark Daniel Mc Dade
- Nilesh Deshbandhu Gupta
- Vinita Deshbandhu Gupta
- Punita Lal
- Alfonso Martin Gimenez Zulueta
- Jeffrey Bruce Kindler
- Amit Kumar Gupta
- Manju Deshbandhu Gupta
- Jean Luc Marie Martial Belingard
- Amit Kumar Gupta
The primary industry of Lupin Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Lupin Limited is listed on both BSE (code: 500257) and NSE (symbol: LUPIN).
Lupin Limited can be reached at the registered office: Kalpataru Inspire 3Rd Floor Off Western Express Highway Santacruz , East, Mumbai, Maharashtra, India – 400055, or through the website lupin.com.